Another antibody for CALR is in clinical trials - MPN Voice

MPN Voice

10,438 members14,388 posts

Another antibody for CALR is in clinical trials

CanadaG profile image
9 Replies

Hi All, I just heard about another antibody treatment for CALR MF and ET that is in clinical trials with Janssen (J&J). Incyte of course also has one in the clinic (also Phase 1). This is very good news. It's still early days but nice to see another potential treatment option being tested.

link below:

pdf.sciencedirectassets.com...

Written by
CanadaG profile image
CanadaG
To view profiles and participate in discussions please or .
9 Replies
Bariton profile image
Bariton

CanadaG, interesting indeed, but not the kind of literature that most of us read. Are you a scientist yourself? Also, I assume we will need another 6 or 7 years to finalise development of this product, and hope that it ever gets that far.

CanadaG profile image
CanadaG in reply to Bariton

Bariton, I'm not a scientist, I'm a patient. Yes I didn't fully understand it either but I think it is a very positive development

dbus1417 profile image
dbus1417

This is awesome news. My hematologist at md Anderson mentioned this to me yesterday at my quarterly blood check (I have CALR). Lots to be excited about. ✌🏽

CanadaG profile image
CanadaG in reply to dbus1417

Indeed it is! Fingers crossed. Nice to have another trial in addition to Incyte's

dbus1417 profile image
dbus1417 in reply to CanadaG

Yep, I am only 40 so my doctor said we are gonna roll with pegasys until one of these is proven out and then bam!

Tyce500 profile image
Tyce500

Hi, am guessing these trials are not in the UK at present?

CanadaG profile image
CanadaG in reply to Tyce500

I'm not sure but I found this:

isrctn.com/ISRCTN79300015

welshhuw profile image
welshhuw

Thank you for posting. I was aware of the Incyte trial with the INCA033989 antibody currently in early Phase I but it's good to know that another antibody candidate is also under development. Encouraging news for all of us CARLmut patients.

TLJ-1 profile image
TLJ-1

This is indeed good news. They have reported preclinical research on an antibody to all of the CALR mutants. The nice twist for this particular antibody is that it was designed so that it not only binds to the mutant CALR, but it also has another moiety that binds T cells. So, the mechanism is to attract T cells, which will then kill those cells containing the CALR mutant. Of course, this lowers the burden of the mutant with the potential to reduce (reverse even?) progression of the disease and diminish symptoms. The work reported only covers mouse models and blood samples from patients.

Indeed, it will take a long time to see if this will prove clinically useful to patients, but it is good to have an additional approach to our disease.

You may also like...

Clinical trial

be tiring. Also the side affects sound bit daunting. Has anyone been in these clinical trials? I...

Clinical Trial Exceed ET

for the treatment of Essential Thrombocythemia. It has been approved for use in the treatment of...

Share Your Thoughts on Clinical Trials- Take Our Survey

companies and government officials. They know clinical trial participation is very low and they...

Webinar re. MPN Clinical Trials as an Option

consider an MPN clinical trial? In this webinar, Dr. Ruben Mesa will provide an overview of...

Great results from Mylofibrosis clinical trial.

I’ll add another photo in the comments if I can. It’s one that mentions what she’s been taking. But...